Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.64
UTHR's Cash to Debt is ranked higher than
62% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. UTHR: 2.64 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.69   Max: 15951.56
Current: 2.64

0.69
15951.56
Equity to Asset 0.57
UTHR's Equity to Asset is ranked higher than
67% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. UTHR: 0.57 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.97
Current: 0.57

0.37
0.97
Interest Coverage 16.20
UTHR's Interest Coverage is ranked higher than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 16.20 )
UTHR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 3302.25
Current: 16.2

2.02
3302.25
F-Score: 6
Z-Score: 6.15
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.94
UTHR's Operating margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. UTHR: 26.94 )
UTHR' s 10-Year Operating margin (%) Range
Min: -13300   Max: 46.03
Current: 26.94

-13300
46.03
Net-margin (%) 15.74
UTHR's Net-margin (%) is ranked higher than
91% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. UTHR: 15.74 )
UTHR' s 10-Year Net-margin (%) Range
Min: -12800   Max: 56.09
Current: 15.74

-12800
56.09
ROE (%) 15.66
UTHR's ROE (%) is ranked higher than
94% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. UTHR: 15.66 )
UTHR' s 10-Year ROE (%) Range
Min: -95.31   Max: 30.84
Current: 15.66

-95.31
30.84
ROA (%) 9.54
UTHR's ROA (%) is ranked higher than
93% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. UTHR: 9.54 )
UTHR' s 10-Year ROA (%) Range
Min: -85.24   Max: 26.08
Current: 9.54

-85.24
26.08
ROC (Joel Greenblatt) (%) 70.10
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. UTHR: 70.10 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1863.16   Max: 106.93
Current: 70.1

-1863.16
106.93
Revenue Growth (%) 27.40
UTHR's Revenue Growth (%) is ranked higher than
92% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. UTHR: 27.40 )
UTHR' s 10-Year Revenue Growth (%) Range
Min: 25.8   Max: 317.9
Current: 27.4

25.8
317.9
EBITDA Growth (%) 25.50
UTHR's EBITDA Growth (%) is ranked higher than
92% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. UTHR: 25.50 )
UTHR' s 10-Year EBITDA Growth (%) Range
Min: -56   Max: 127.7
Current: 25.5

-56
127.7
EPS Growth (%) 20.60
UTHR's EPS Growth (%) is ranked higher than
90% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. UTHR: 20.60 )
UTHR' s 10-Year EPS Growth (%) Range
Min: -50.4   Max: 153.6
Current: 20.6

-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

UTHR Guru Trades in Q4 2013

Steven Cohen 24,174 sh (New)
Paul Tudor Jones 5,100 sh (-33.77%)
Joel Greenblatt 194,595 sh (-47.71%)
Jim Simons 224,278 sh (-49.12%)
John Hussman 134,000 sh (-62.57%)
» More
Q1 2014

UTHR Guru Trades in Q1 2014

Paul Tudor Jones 9,167 sh (+79.75%)
Joel Greenblatt 316,489 sh (+62.64%)
Jim Simons 287,940 sh (+28.39%)
John Hussman 134,000 sh (unchged)
Steven Cohen 2,497 sh (-89.67%)
» More
Q2 2014

UTHR Guru Trades in Q2 2014

Joel Greenblatt 646,066 sh (+104.14%)
John Hussman 134,000 sh (unchged)
Paul Tudor Jones 8,168 sh (-10.9%)
Jim Simons 252,478 sh (-12.32%)
» More
Q3 2014

UTHR Guru Trades in Q3 2014

Steven Cohen 8,700 sh (New)
Jean-Marie Eveillard 262,080 sh (New)
Joel Greenblatt 288,401 sh (-55.36%)
John Hussman 50,000 sh (-62.69%)
Paul Tudor Jones 3,019 sh (-63.04%)
Jim Simons 2,378 sh (-99.06%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-09-30 Reduce -62.69%0.57%$86.44 - $136.16 $ 131.2228%50000
Joel Greenblatt 2014-09-30 Reduce -55.36%0.4%$86.44 - $136.16 $ 131.2228%288401
Jean-Marie Eveillard 2014-09-30 New Buy0.08%$86.44 - $136.16 $ 131.2228%262080
Joel Greenblatt 2014-06-30 Add 104.14%0.37%$86.14 - $107.81 $ 131.2236%646066
Joel Greenblatt 2014-03-31 Add 62.64%0.17%$90.67 - $113.39 $ 131.2228%316489
John Hussman 2013-12-31 Reduce -62.57%1%$80.03 - $114.51 $ 131.2246%134000
Joel Greenblatt 2013-12-31 Reduce -47.71%0.45%$80.03 - $114.51 $ 131.2246%194595
John Hussman 2013-09-30 Reduce -23.5%0.33%$66.1 - $79.58 $ 131.2280%358000
Vanguard Health Care Fund 2013-09-30 Sold Out 0.32%$66.1 - $79.58 $ 131.2280%0
David Dreman 2013-09-30 Sold Out 0.12%$66.1 - $79.58 $ 131.2280%0
Joel Greenblatt 2013-06-30 Add 15.34%0.13%$59.64 - $69.31 $ 131.22104%341330
HOTCHKIS & WILEY 2012-12-31 Sold Out 0.09%$44.99 - $58.91 $ 131.22152%0
David Dreman 2012-12-31 New Buy0.09%$44.99 - $58.91 $ 131.22152%57025
John Hussman 2012-09-30 New Buy0.67%$49.73 - $58.2 $ 131.22142%500000
HOTCHKIS & WILEY 2012-09-30 Add 270.56%0.06%$49.73 - $58.2 $ 131.22142%266800
Joel Greenblatt 2012-06-30 Add 101.59%0.6%$41.19 - $49.51 $ 131.22197%332744
Richard Perry 2012-06-30 Sold Out 0.04%$41.19 - $49.51 $ 131.22197%0
HOTCHKIS & WILEY 2012-06-30 New Buy0.02%$41.19 - $49.51 $ 131.22197%72000
Joel Greenblatt 2012-03-31 Add 82.68%0.31%$45.54 - $50.99 $ 131.22190%165063
Richard Perry 2012-03-31 New Buy0.04%$45.54 - $50.99 $ 131.22190%15300
Joel Greenblatt 2011-12-31 Add 38.75%0.15%$37.21 - $47.54 $ 131.22216%90355
Joel Greenblatt 2011-09-30 Add 274.82%0.29%$37.47 - $57.38 $ 131.22171%65122
Vanguard Health Care Fund 2011-09-30 Add 77.9%0.16%$37.47 - $57.38 $ 131.22171%1787000
Michael Price 2011-09-30 Sold Out 0.1%$37.47 - $57.38 $ 131.22171%0
George Soros 2011-09-30 Sold Out 0.0776%$37.47 - $57.38 $ 131.22171%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about United Therapeutics Corp

High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares
Yesterday insider executives made large sells at Facebook Inc. (FB), United Therapeutics Corporation (UTHR) and Hillenbrand Inc. (HI), all companies held by billionaires. Here are the company updates and trade highlights. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.60
UTHR's P/E(ttm) is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 38.60 )
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83   Max: 218.78
Current: 38.6

8.83
218.78
P/B 5.27
UTHR's P/B is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. UTHR: 5.27 )
UTHR' s 10-Year P/B Range
Min: 2.01   Max: 10.39
Current: 5.27

2.01
10.39
P/S 5.82
UTHR's P/S is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. UTHR: 5.82 )
UTHR' s 10-Year P/S Range
Min: 2.83   Max: 18.02
Current: 5.82

2.83
18.02
PFCF 21.41
UTHR's PFCF is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 21.41 )
UTHR' s 10-Year PFCF Range
Min: 9.7   Max: 1199.4
Current: 21.41

9.7
1199.4
EV-to-EBIT 17.26
UTHR's EV-to-EBIT is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 17.26 )
UTHR' s 10-Year EV-to-EBIT Range
Min: -163.7   Max: 363.2
Current: 17.26

-163.7
363.2
PEG 0.56
UTHR's PEG is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 0.56 )
UTHR' s 10-Year PEG Range
Min: 0.62   Max: 0.75
Current: 0.56

0.62
0.75
Shiller P/E 45.09
UTHR's Shiller P/E is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 45.09 )
UTHR' s 10-Year Shiller P/E Range
Min: 24.86   Max: 129.35
Current: 45.09

24.86
129.35
Current Ratio 1.42
UTHR's Current Ratio is ranked higher than
54% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. UTHR: 1.42 )
UTHR' s 10-Year Current Ratio Range
Min: 0.96   Max: 64.22
Current: 1.42

0.96
64.22
Quick Ratio 1.33
UTHR's Quick Ratio is ranked higher than
56% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. UTHR: 1.33 )
UTHR' s 10-Year Quick Ratio Range
Min: 0.9   Max: 64.22
Current: 1.33

0.9
64.22

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 486.00
UTHR's Price/Net Current Asset Value is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. UTHR: 486.00 )
UTHR' s 10-Year Price/Net Current Asset Value Range
Min: 1.47   Max: 476.48
Current: 486

1.47
476.48
Price/Tangible Book 5.33
UTHR's Price/Tangible Book is ranked higher than
80% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. UTHR: 5.33 )
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 17.88
Current: 5.33

1.16
17.88
Price/DCF (Projected) 1.72
UTHR's Price/DCF (Projected) is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 1.72 )
UTHR' s 10-Year Price/DCF (Projected) Range
Min: 1.38   Max: 232.67
Current: 1.72

1.38
232.67
Price/Median PS Value 0.76
UTHR's Price/Median PS Value is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. UTHR: 0.76 )
UTHR' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 328.57
Current: 0.76

0.43
328.57
Price/Peter Lynch Fair Value 1.54
UTHR's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 1.54 )
UTHR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.39   Max: 5.82
Current: 1.54

0.39
5.82
Price/Graham Number 2.76
UTHR's Price/Graham Number is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 2.76 )
UTHR' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.79
Current: 2.76

0.99
5.79
Earnings Yield (Greenblatt) 5.80
UTHR's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. UTHR: 5.80 )
UTHR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 19
Current: 5.8

0.3
19
Forward Rate of Return (Yacktman) 57.02
UTHR's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. UTHR: 57.02 )
UTHR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.2   Max: 57.6
Current: 57.02

-50.2
57.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany
United Therapeutics Corp was incorporated in Delaware in June 1996. The Company is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic and life-threatening conditions. The Company operates in two business segments: pharmaceuticals and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of its therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient cardiac monitoring products and services. Its therapeutic products include: Prostacyclin analogues (Remodulin, Tyvaso, Orenitram, 314d, TransCon treprostinil and TransCon beraprost), Phosphodiesterase type 5 (PDE-5) inhibitor (Adcirca), Monoclonal antibody for oncologic applications, Glycobiology antiviral agents, Cell-based therapy, and Lung transplantation. The Company competes with the developers, manufacturers and distributors of all of these products for customers, funding, access to licenses, personnel, third-party collaborators, product development and commercialization.
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
comment on UTHR May 11 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
comment on UTHR Mar 23 2013 
fd Jan 12 2013 


More From Other Websites
Stock Market Today: Top Biotech Is Near Buy Point Nov 26 2014
UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers Nov 13 2014
Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors Nov 13 2014
Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors Nov 13 2014
United Therapeutics downgraded by Argus Nov 03 2014
UNITED THERAPEUTICS CORP Financials Nov 01 2014
10-Q for United Therapeutics Corp. Oct 30 2014
United Therapeutics Falls on Q3 Loss, Revenues Miss Oct 29 2014
Q3 2014 United Therapeutics Corp Earnings Release - Before Market Open Oct 28 2014
United Therapeutics reports 3Q loss Oct 28 2014
United Therapeutics reports 3Q loss Oct 28 2014
UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition Oct 28 2014
UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report Oct 28 2014
United Therapeutics Corporation Reports Third Quarter 2014 Financial Results Oct 28 2014
Biotechs Show Fed Chief's Not Much Of A Stock Analyst Oct 22 2014
United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open... Oct 21 2014
United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open... Oct 21 2014
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Oct 14 2014
Can the Uptrend Continue for United Therapeutics (UTHR)? Sep 24 2014
Today's Market Thorns, Roses, and All Time Highs... Sep 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK